SCHEMBL4166302

SCHEMBL4166302

N[C@H](COCc1ccccc1)c1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 7/20 0.47
TAAR1 Q96RJ0 1/20 0.42
SCN10A Q9Y5Y9 2/20 0.41
ROCK2 O75116 4/20 0.41
GPR39 O43194 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
RAB9A P51151 2/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38
TUBA1A Q71U36 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5103917 1.00 TACR1 (0.47) TACR1TAAR1SCN10AROCK2GPR39
SCHEMBL5111361 0.86 ROCK2 (0.47) TAAR1ROCK2OPRM1OPRD1CTDSP1
SCHEMBL5110751 0.83 TAAR1 (0.42) TAAR1SCN10AROCK2RAB9AKDM4E
SCHEMBL6525600 0.83 TAAR1 (0.42) TAAR1SCN10AROCK2RAB9AKDM4E
Hydrochloric Acid SCHEMBL29630186 0.83 TAAR1 (0.57) TACR1TAAR1SCN10ARAB9A
Hydrochloric Acid SCHEMBL27090434 0.83 TAAR1 (0.57) TACR1TAAR1SCN10ARAB9A
Hydrochloric Acid SCHEMBL27149224 0.83 TAAR1 (0.57) TACR1TAAR1SCN10ARAB9A
SCHEMBL4162306 0.82 TAAR1 (0.43) TAAR1SCN10AROCK2RAB9AKDM4E
SCHEMBL583539 0.82 TAAR1 (0.43) TAAR1SCN10AROCK2RAB9AKDM4E
SCHEMBL1479674 0.82 TAAR1 (0.43) TAAR1SCN10AROCK2RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
EP-1583757-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-10-12 EP disclosed
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-09 US disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions F11, F12, F2 TACR1 2931/4885TAAR1 1160/4885SCN10A 485/4885
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 TACR1 2807/4885TAAR1 1512/4885SCN10A 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.